InnoCan Pharma (TSE:INNO) has released an update.
InnoCan Pharma has enlisted Dr. William K. Schmidt, a renowned pain management expert, to bolster their FDA submission of LPT-CBD for chronic pain treatment. Dr. Schmidt’s extensive experience in clinical drug development, particularly in pain medication, is expected to significantly strengthen the company’s bid for FDA approval. InnoCan Pharma is known for its focus on pharmaceutical technologies and wellness products that aim to enhance patients’ quality of life.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
